3. Due to reactive metabolite species for VKTX, can company comment on the metabolite being a CYP P450 3A4 covalent inhibitor? Data for similar reactive species in literature shows this could be a major problem for concomitant drugs to be source for drug-drug interaction. (Note that 3A4 is the source for the reactive metabolite.) Jim, since VK2809 is a prodrug wouldn't that help mitigate drug/drug interactions? seemed ok pre-clinic... https://www.ncbi.nlm.nih.gov/pubmed/19183199/ MB07811/VK2809 in combination with atorvastatin in rabbits, dogs and monkeys. Before advancing to a NASH phase 3, wouldn't VK2809 be required to go through a phase 2 statin/combo trial and a NASH phase 2 with biopsies?